Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Amitifadine hydrochloride; DOV-21947; EB-1010

Latest Information Update: 09 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DOV Pharmaceutical
  • Developer Euthymics Bioscience
  • Class Antidepressants; Chlorobenzenes; Pyrrolidines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alcoholism; Smoking withdrawal
  • Discontinued Major depressive disorder; Obesity

Most Recent Events

  • 01 Nov 2017 Ethismos Research acquires intellectual property assets of amitifadine from Euthymics Bioscience
  • 21 Sep 2017 Discontinued - Phase-II/III for Major depressive disorder (Second-line therapy or greater) in USA (PO) (Euthymics Bioscience website, September 2017)
  • 21 Sep 2017 Preclinical trials in Alcoholism in USA (PO) before September 2017 (Euthymics Bioscience website, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top